BeOne Medicines (ONC) Short term Debt (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Short term Debt of $116.1 million for Q1 2026, down 84.79% year-over-year from $763.5 million in Q1 2025, and up 102.71% quarter-over-quarter from $57.3 million in Q4 2025.
BeOne Medicines (ONC) Short term Debt (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Short term Debt for 11 consecutive years, with $116.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt fell 84.79% year-over-year to $116.1 million; the TTM figure through Mar 2026 stood at $116.1 million (down 84.79% YoY), while the FY2025 annual figure was $57.3 million, down 93.27% from the prior year.
- Short term Debt climbed to $116.1 million in Q1 2026 per ONC's latest filing, from $57.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $863.8 million in Q3 2024 and bottomed at $50.0 million in Q4 2022.
- Historically, Short term Debt has averaged $481.8 million across 5 years, with a median of $421.1 million in 2023.
- Annual changes were most pronounced in 2023 — Short term Debt soared 1276.73% — and 2025, when it tumbled 93.95%.
- BeOne Medicines' Short term Debt stood at $50.0 million in 2022, then jumped by 1276.73% to $688.4 million in 2023, then gained by 23.7% to $851.5 million in 2024, then tumbled by 93.27% to $57.3 million in 2025, then soared by 102.71% to $116.1 million in 2026.
- Business Quant data shows ONC's Short term Debt at $116.1 million in Q1 2026, $57.3 million in Q4 2025, and $52.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190.90 Mn |
| Mar 31, 2026 | 116.14 Mn |
| Dec 31, 2025 | 57.29 Mn |
| Sep 30, 2025 | 52.25 Mn |
| Jun 30, 2025 | 808.39 Mn |
| Mar 31, 2025 | 763.47 Mn |
| Dec 31, 2024 | 851.53 Mn |
| Sep 30, 2024 | 863.80 Mn |
| Jun 30, 2024 | 851.66 Mn |
| Mar 31, 2024 | 826.97 Mn |
| Dec 31, 2023 | 688.37 Mn |
| Sep 30, 2023 | 328.56 Mn |
| Jun 30, 2023 | 421.05 Mn |
| Mar 31, 2023 | 281.81 Mn |
| Dec 31, 2022 | 50.00 Mn |
| Sep 30, 2022 | 441.28 Mn |
| Jun 30, 2022 | 380.73 Mn |
| Mar 31, 2022 | 407.39 Mn |
| Dec 31, 2021 | 427.57 Mn |
| Sep 30, 2021 | 442.37 Mn |